Inozyme Pharma, Inc. (INZY) DCF Valuation

Valoración de DCF Innozyme Pharma, Inc. (Inzy)

US | Healthcare | Biotechnology | NASDAQ
Inozyme Pharma, Inc. (INZY) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Inozyme Pharma, Inc. (INZY) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Descubra el verdadero potencial de Inozyme Pharma, Inc. (Inzy) con nuestra calculadora DCF avanzada! Ajuste los supuestos clave, explore diversos escenarios y evalúe cómo los diferentes cambios afectan la valoración de la farmacéutica de la inozima, todo dentro de una sola plantilla de Excel.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -20.7 -56.8 -56.0 -65.9 -74.8 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .1 .2 1.1 1.2 .8 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -20.8 -57.0 -57.0 -67.1 -75.6 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 47.1 159.9 111.8 127.9 188.6 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .1 .2 .1 .1 .4
Account Receivables, % 100 100 100 100 100
Inventories .0 -12.4 -.1 -.1 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .9 3.1 2.4 2.5 1.2 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -.1 -.6 -.4 -.4 -.3 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -19.6 -56.4 -56.8 -65.4 -75.6 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -18.9 -42.3 -69.0 -64.5 -76.9 -.8 .0 .0 .0 .0
WACC, % 10.55 10.63 10.64 10.6 10.64 10.61 10.61 10.61 10.61 10.61
PV UFCF
SUM PV UFCF -.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt 12
Equity Value -13
Diluted Shares Outstanding, MM 52
Equity Value Per Share -0.25

What You Will Get

  • Real INZY Financial Data: Pre-filled with Inozyme Pharma’s historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Inozyme Pharma’s intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Accurate Inozyme Financials: Gain access to reliable pre-loaded historical data and future forecasts.
  • Tailored Forecast Assumptions: Modify highlighted cells for key metrics like WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • Interactive Dashboard: Clear charts and summaries to effectively visualize your valuation outcomes.
  • Designed for All Users: A user-friendly layout suitable for investors, CFOs, and consultants alike.

How It Works

  1. Step 1: Download the Excel file for Inozyme Pharma, Inc. (INZY).
  2. Step 2: Review Inozyme’s pre-filled financial data and projections.
  3. Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
  5. Step 5: Evaluate the outputs and leverage the findings for your investment strategies.

Why Choose This Calculator for Inozyme Pharma, Inc. (INZY)?

  • Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Inozyme Pharma.
  • Customizable Inputs: Modify the yellow-highlighted cells to explore different financial scenarios.
  • Detailed Insights: Automatically computes Inozyme’s intrinsic value and Net Present Value.
  • Preloaded Data: Historical and projected data provide a solid foundation for analysis.
  • Professional Quality: Perfect for financial analysts, investors, and business consultants focused on Inozyme Pharma.

Who Should Use This Product?

  • Biotechnology Students: Understand drug development processes and apply them using real-world data.
  • Researchers: Integrate advanced models into academic studies or clinical research.
  • Investors: Evaluate your investment strategies and analyze the market performance of Inozyme Pharma, Inc. (INZY).
  • Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
  • Healthcare Entrepreneurs: Discover how large biotech companies like Inozyme Pharma, Inc. (INZY) are assessed in the market.

What the Template Contains

  • Historical Data: Includes Inozyme Pharma, Inc.’s past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Inozyme Pharma, Inc.'s intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Inozyme Pharma, Inc.’s financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.